SEC Stock Data Quick Answer Ads-Tec Energy Public Ltd Co reported R&D Expense of $8.97 million for fiscal year 2024. Ads-Tec Energy Public Ltd Co R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2024 $8.97M +216.8% 2023 $2.83M +66.5% 2022 $1.70M -15.5% 2021 $2.01M +168.6% 2020 $749.0K +58.4% 2019 $473.0K — Ads-Tec Energy Public Ltd … Read more
Quick Answer Ads-Tec Energy Public Ltd Co reported Total Assets of $145.23 million for fiscal year 2024. Ads-Tec Energy Public Ltd Co Total Assets — Annual History Fiscal Year Total Assets YoY Change 2024 $145.23M +16.7% 2023 $124.41M -10.8% 2022 $139.44M -7.8% 2021 $151.22M +233.6% 2020 $45.33M — Ads-Tec Energy Public Ltd Co showed an … Read more
Quick Answer Ads-Tec Energy Public Ltd Co reported Total Assets of $145.23 million for fiscal year 2024. Ads-Tec Energy Public Ltd Co — Key Financials by Year Metric 2024 2023 2022 2021 2020 2019 Total Assets $145.23M+16.7% $124.41M-10.8% $139.44M-7.8% $151.22M+233.6% $45.33M — R&D Expense $8.97M+216.8% $2.83M+66.5% $1.70M-15.5% $2.01M+168.6% $749.0K+58.4% $473.0K Gross Profit $19.43M+773.1% -$2.89M+35.5% -$4.47M-96.7% … Read more
Quick Answer Adaptive Biotechnologies Corp reported Shares Outstanding of 153.78 million shares for fiscal year 2025. Adaptive Biotechnologies Corp Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 153.78M +4.1% 2024 147.77M +1.9% 2023 145.08M +1.4% 2022 143.11M +1.2% 2021 141.39M +2.7% 2020 137.65M +9.9% 2019 125.24M +875.3% 2018 12.84M — Quarterly … Read more
Quick Answer Adaptive Biotechnologies Corp reported Operating Income of -$57.12 million for fiscal year 2025. Adaptive Biotechnologies Corp Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$57.12M +64.9% 2024 -$162.55M +28.4% 2023 -$227.03M -13.4% 2022 -$200.19M +4.2% 2021 -$208.97M -36.7% 2020 -$152.82M -94.9% 2019 -$78.39M -57.6% 2018 -$49.76M -11.9% 2017 -$44.48M … Read more
Quick Answer Adaptive Biotechnologies Corp reported R&D Expense of $93.77 million for fiscal year 2025. Adaptive Biotechnologies Corp R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $93.77M -8.9% 2024 $102.95M -15.7% 2023 $122.12M -13.9% 2022 $141.76M -0.4% 2021 $142.34M +22.6% 2020 $116.07M +64.2% 2019 $70.70M +80.6% 2018 $39.16M +22.4% 2017 $32.00M … Read more
Quick Answer Adaptive Biotechnologies Corp reported Stockholders Equity of $218.79 million for fiscal year 2025. Adaptive Biotechnologies Corp Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $218.79M +7.9% 2024 $202.71M -34.3% 2023 $308.40M -33.6% 2022 $464.17M -23.2% 2021 $603.99M -18.7% 2020 $743.27M +30.2% 2019 $571.04M +321.2% 2018 -$258.11M -14.9% 2017 -$224.62M … Read more
Quick Answer Adaptive Biotechnologies Corp reported Long-Term Debt of $126.57 million for fiscal year 2025. Adaptive Biotechnologies Corp Long-Term Debt — Annual History Fiscal Year Long-Term Debt YoY Change 2025 $126.57M -4.4% 2024 $132.41M +1.3% 2023 $130.66M +4.2% 2022 $125.36M — Quarterly Long-Term Debt Quarter Ending Long-Term Debt YoY QoQ September 30, 2025 $129.41M -2.5% … Read more
Quick Answer Adaptive Biotechnologies Corp reported Cash and Equivalents of $70.50 million for fiscal year 2025. Adaptive Biotechnologies Corp Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $70.50M +47.1% 2024 $47.92M -26.3% 2023 $65.06M -27.7% 2022 $90.03M -35.3% 2021 $139.06M +12.7% 2020 $123.44M +27.8% 2019 $96.58M +75.5% 2018 $55.03M … Read more
Quick Answer Adaptive Biotechnologies Corp reported Total Assets of $512.74 million for fiscal year 2025. Adaptive Biotechnologies Corp Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $512.74M -4.9% 2024 $539.38M -18.4% 2023 $661.13M -22.8% 2022 $856.62M -7.2% 2021 $923.34M -17.3% 2020 $1.12B +22.4% 2019 $912.30M +174.2% 2018 $332.69M — Quarterly Total … Read more